Foghorn Therapeutics Inc (FHTX)

Apr 07, 2025

(FHTX) Technical Data - news.stocktradersdaily.com

Apr 07, 2025

Apr 02, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Apr 02, 2025

Mar 27, 2025

Trend Tracker for (FHTX) - news.stocktradersdaily.com

Mar 27, 2025

Mar 26, 2025

Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha

Mar 26, 2025

Mar 26, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - The AM Reporter

Mar 26, 2025

Mar 25, 2025

Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan

Mar 25, 2025

Mar 24, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World

Mar 24, 2025

Mar 22, 2025

2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World

Mar 22, 2025

Mar 20, 2025

Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com

Mar 20, 2025

Mar 18, 2025

What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World

Mar 18, 2025

Mar 13, 2025

Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks

Mar 13, 2025

Mar 11, 2025

Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Mar 11, 2025

Mar 10, 2025

Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025

Mar 07, 2025

Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks

Mar 07, 2025

Mar 07, 2025

Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks

Mar 07, 2025

Mar 06, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025

Mar 06, 2025

Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com

Mar 06, 2025

Mar 06, 2025

Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq

Mar 06, 2025

Mar 06, 2025

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewswire

Mar 06, 2025

Mar 06, 2025

Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan

Mar 06, 2025

Mar 01, 2025

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN

Mar 01, 2025

Feb 28, 2025

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Canada Finance

Feb 28, 2025

Feb 27, 2025

Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025

Feb 25, 2025

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

Can Foghorn's Gene Traffic Control Platform Impress Investors at Upcoming Healthcare Conferences? - StockTitan

Feb 25, 2025

Feb 24, 2025

How To Trade (FHTX) - Stock Traders Daily

Feb 24, 2025

Feb 24, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Feb 24, 2025

Feb 23, 2025

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking - Simply Wall St

Feb 23, 2025

Feb 19, 2025

Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health – Company Announcement - Financial Times

Feb 19, 2025

Feb 17, 2025

Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Feb 17, 2025

Feb 14, 2025

FHTX Stock Price and Chart — NASDAQ:FHTX - TradingView

Feb 14, 2025

Feb 12, 2025

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? - MSN

Feb 12, 2025

Feb 12, 2025

Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace

Feb 12, 2025

Feb 11, 2025

Eagle financial services executive buys $3,200 in stock - MSN

Feb 11, 2025

Feb 11, 2025

CENX’s Stock Woes: Up 59.32% in 6 Months, Up 59.32% in Just 5 Days - The InvestChronicle

Feb 11, 2025

Feb 10, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Feb 10, 2025

Feb 10, 2025

Harmony Gold Mining Co Ltd ADR (HMY) Stock: A Study of the Market Performance - The News Heater

Feb 10, 2025

Feb 10, 2025

Foghorn Therapeutics Inc (FHTX) Shares Up Despite Recent Market Volatility - The News Heater

Feb 10, 2025

Feb 08, 2025

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks - Markets Insider

Feb 08, 2025

Feb 07, 2025

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Feb 07, 2025

Feb 06, 2025

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Yahoo Finance

Feb 06, 2025

Feb 06, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Yahoo Finance

Feb 06, 2025

Feb 06, 2025

What is B. Riley's Forecast for FHTX FY2024 Earnings? - MarketBeat

Feb 06, 2025

Feb 05, 2025

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance

Feb 05, 2025

Feb 05, 2025

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - Yahoo Finance

Feb 05, 2025

Feb 05, 2025

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance

Feb 05, 2025